Cargando…

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609924/ https://www.ncbi.nlm.nih.gov/pubmed/34810236 http://dx.doi.org/10.1136/jitc-2021-002444corr1

Ejemplares similares

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Correction: Analysis of zero inflated dichotomous variables from a Bayesian perspective: application to occupational health
por: Moriña, David, et al.
Publicado: (2022)

Corticostriatal Projection Neurons – Dichotomous Types and Dichotomous Functions
por: Reiner, Anton, et al.
Publicado: (2010)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
Publicado: (2023)

Author Correction: A new approach to produce IgG(4)-like bispecific antibodies
por: Zhao, Caizhi, et al.
Publicado: (2022)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Publisher Correction: Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management
por: Barrière, David André, et al.
Publicado: (2020)

Dichotomous Engagement of HDAC3 Activity Governs Inflammatory Responses
por: Nguyen, Hoang C. B., et al.
Publicado: (2020)

A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies
por: Shepherd, Alex, et al.
Publicado: (2023)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
por: Jarantow, Stephen W., et al.
Publicado: (2015)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Correction: Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces
por: Warszawski, Shira, et al.
Publicado: (2020)

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
por: Mandrup, Ole A., et al.
Publicado: (2021)

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
por: Van Blarcom, Thomas, et al.
Publicado: (2017)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
por: Yu, Lin, et al.
Publicado: (2021)

Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
por: Pan, Zhidi, et al.
Publicado: (2022)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
por: Haber, Lauric, et al.
Publicado: (2021)

Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin
por: Nilvebrant, Johan, et al.
Publicado: (2014)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m5ltc5k8jm7i8pipcckqfnsm3o